The Global Health Body Issues Warning Over Severe Lack of Obesity Injections

Fewer than one in 10 individuals eligible to benefit from GLP-1 drugs like Wegovy can access them, warns the World Health Organization as it issues its first guidance on the therapies.

Given in excess of 1,000,000,000 individuals worldwide currently classified as obese, it is advocating for more widespread and fairer access to GLP-1 medication.

Per estimates, more than two billion could be living with obesity by 2030 unless action is taken.

"The latest guidance affirms that obesity is a chronic disease that can be managed with holistic and ongoing treatment," stated its chief Tedros Adhanom Ghebreyesus.

Significant expense, limited production capacity, and supply-chain constraints are significant barriers to broad access to the injections that can aid individuals in losing significant body mass, says the body.

Weight-Loss Drug Shortage

Even in the current best projected case, the production of these medications might only reach about 100 million people – fewer than 10% of those who need them, as stated by the health organization.

The recommendation calls on nations and manufacturers to expand availability, through measures like patent sharing.

Exclusive production rights on a key compound – the main ingredient of a leading brand – is due to expire in multiple nations in 2026.

The Way Weight-Loss Drugs Operate

These medications replicate a natural hormone to delay gastric emptying, curb appetite and increase the sense of being full so individuals reduce food intake.

Individuals commonly begin shedding pounds after several weeks of commencing the once-weekly jabs.

Research indicates patients may put most of the weight back on within a year of halting the drug, as their usual food cravings resume.

To be carrying excess weight increases your chance for developing diseases, including diabetes, cardiovascular issues, stroke, and specific malignancies.

Obesity impacts individuals in every country and was linked to millions of fatalities worldwide in 2024, per the WHO.